Chronic supplementation of beta-hydroxy-beta methylbutyrate (HMβ) increases the activity of the GH/IGF-I axis and induces hyperinsulinemia in rats.

Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of São Paulo. Av. Prof. Lineu Prestes, São Paulo/SP, Brazil.
Growth hormone & IGF research: official journal of the Growth Hormone Research Society and the International IGF Research Society (Impact Factor: 1.33). 04/2011; 21(2):57-62. DOI: 10.1016/j.ghir.2010.12.006
Source: PubMed

ABSTRACT Beta-hydroxy-beta-methylbutyrate (HMβ) is a metabolite of leucine widely used for improving sports performance. Although HMβ is recognized to promote anabolic or anti-catabolic effects on protein metabolism, the impact of its long-term use on skeletal muscle and/or genes that control the skeletal protein balance is not fully known. This study aimed to investigate whether chronic HMβ treatment affects the activity of GH/IGF-I axis and skeletal muscle IGF-I and myostatin mRNA expression.
Rats were treated with HMβ (320mg/kg BW) or vehicle, by gavage, for 4 weeks, and killed by decapitation. Blood was collected for evaluation of serum insulin, glucose and IGF-I concentrations. Samples of pituitary, liver, extensor digitorum longus (EDL) and soleus muscles were collected for total RNA or protein extraction to evaluate the expression of pituitary growth hormone (GH) gene (mRNA and protein), hepatic insulin-like growth factor I (IGF-I) mRNA, skeletal muscle IGF-I and myostatin mRNA by Northern blotting/real time-PCR, or Western blotting.
Chronic HMβ treatment increased the content of pituitary GH mRNA and GH, hepatic IGF-I mRNA and serum IGF-I concentration. No changes were detected on skeletal muscle IGF-I and myostatin mRNA expression. However, the HMβ-treated rats although normoglycemic, exhibited hyperinsulinemia.
The data presented herein extend the body of evidence on the potential role of HMβ-treatment in stimulating GH/IGF-I axis activity. In spite of this effect, HMβ supplementation also induces an apparent insulin resistance state which might limit the beneficial aspects of the former results, at least in rats under normal nutritional status and health conditions.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: In recent years, several investigations have related -hydroxy--methylbutyrate (HMB) to a reduced muscle proteolysis and to an increase in muscle mass. Therefore, a number of studies focused on the cellular and molecular mechanisms regulating these effects have been carried out. AIMS: The objectives of this review are: to know both HMB metabolism and toxicity, and to identify HMB cellular and molecular mechanisms of action when used as a dietary supplement. METHODS: A search was performed in the Web of Science, Pubmed and SportDiscus data bases. RESULTS were divided into two parts; this article presents aspects referring to HMB mechanisms of action. RESULTS: There is insufficient evidence that HMB intake increases muscle cholesterol synthesis. It probably has positive effects on muscle metabolism through both the mTOR and ubiquitin-proteasome pathways, although the mechanism of action is unknown. HMB may increase blood levels of -hydroxybutyrate and this could explain the main effects of HMB on muscle proteolysis. CONCLUSION: According to these results, the possibility of justifying the action of HMB through the beta-hydroxybutyrate pathway opens an interesting line of research for future studies.
    Nutricion hospitalaria: organo oficial de la Sociedad Espanola de Nutricion Parenteral y Enteral 01/2015; 31:597-605. · 1.25 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective. To examine the endocrine response to a bout of heavy resistance exercise following acute β-hydroxy-β-methylbutyrate free acid (HMB-FA) ingestion. Design. Twenty resistance trained men were randomized and consumed either 1 g of HMB-FA (BetaTor) or placebo (PL) 30 min prior to performing an acute heavy resistance exercise protocol. Blood was obtained before (PRE), immediately after (IP), and 30 min after exercise (30P). Circulating concentrations of testosterone, growth hormone (GH), insulin-like growth factor (IGF-1), and insulin were assayed. Data were analyzed with a repeated measures ANOVA and area under the curve (AUC) was analyzed by the trapezoidal rule. Results. The resistance exercise protocol resulted in significant elevations from PRE in testosterone , GH , and insulin at IP, with GH and insulin remaining elevated at 30P. A significant interaction was noted between groups in the plasma GH response at IP, which was significantly higher following HMB-FA compared to PL . AUC analysis revealed an elevated GH and IGF-1 response in the HMB-FA group compared to PL. Conclusion. HMB-FA prior to resistance exercise augments the GH response to high volume resistance exercise compared to PL. These findings provide further support for the potential anabolic benefits associated with HMB supplementation.
    International Journal of Endocrinology 01/2015; 2015:1-7. DOI:10.1155/2015/856708 · 1.52 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The objective of this study was to determine the effects of potassium diformate (KDF) on growth performance of weaning piglets and genes expression related with growth axis and hepatic gluconeogenesis. A total of 180 piglets weaned at 28 d of age were allocated randomly into two groups, with 6 pens in each group and 15 piglets in each pen. Piglets in the control group were fed basal diet, whereas the KDF-treated group was fed basal diet supplemented with 10 g/kg KDF. After 5 weeks feeding, KDF-treated piglets showed higher average daily feed intake (ADFI) and average daily bodyweight gain (ADG) than those of the control (P<0.05), whereas the feed conversion ratio (FCR) was lower than that of the control (P=0.02). The apparent digestibility of dry matter and crude protein of the KDF-treated group were higher than those of the control group (P<0.01). KDF treatment did not change the blood indices level of insulin-like growth factor-I (IGF-I), high density lipoprotein (HDL), low density lipoprotein (LDL), total cholesterol (TC), triglyceride (TG) and blood glucose (BG) in plasma. KDF treatment did not influence the mRNA expression of growth hormone releasing hormone (GHRH) and somatostatin (SS) in hypothalamus, and the levels of growth hormone receptor (GHR) and IGF-I receptor (IGF-IR) mRNA in pituitary. Whereas, it increased the abundance of GH mRNA in pituitary, and the mRNA of GHR, IGF-I, IGF-IR, glucose-6-phosphatase (G6PC), fructose-1,6-bisphosphatase (FBP) and phosphoenolpyruvate carboxykinase (PCK) in liver (P<0.05). Furthermore, KDF treatment increased the concentration of IGF-I peptide in liver (P=0.000). These results suggest that, the beneficial effect of KDF on the growth performance may relate to the regulation of the GH axis and glucose homeostasis in piglets.
    Livestock Science 02/2015; 172:85-90. DOI:10.1016/j.livsci.2014.12.003 · 1.10 Impact Factor


Available from
May 21, 2014